Sabitlenmiş Tweet
Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature
nature.com/articles/s4158… @MDAndersonNews
English
Ghayas Issa
153 posts
Ghayas Issa
@GhayasIssa
Leukemia Physician at MD Anderson. Research in AML, CML, other leukemias if it's the right genotype. Views expressed here are my own.
Katılım Nisan 2017
296 Takip Edilen785 Takipçiler
Ghayas Issa retweetledi
Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (@GhayasIssa, @MDAndersonNews).
cancerletter.com/trials-and-tri…
English
Ghayas Issa retweetledi
"Our research confirmed the significant benefits and efficacy of this therapy for both adult and pediatric patients," says Dr. Ghayas Issa.
@US_FDA has approved revumenib for some patients with relapsed or refractory acute leukemia: brnw.ch/21wOL2U @GhayasIssa #EndCancer
English
@JZarkaMD @MDAndersonNews Thanks Jabra - how about you come back to work on this? :)
English
Congrats on this achievement @GhayasIssa! It was inspiring to see this blossom from lab to bedside to FDA approval. Our patients are lucky to have you advocating for their care. @MDAndersonNews
Ghayas Issa@GhayasIssa
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
English
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
English
@GhayasIssa Amazing news!! Congrats @GhayasIssa and to all who have contributed to this important advancement for our patients! More to come indeed 😉
English
Fantastic news! Congratulations @GhayasIssa and team! What an amazing advancement in the field! Onwards and upwards 🎊
Ghayas Issa@GhayasIssa
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
English
@GhayasIssa Congrats! @GhayasIssa This is very important news for the AML field. Targeted therapies are undoubtedly the future of AML treatment.
English
Huge news in the acute leukemia therapy field! Thankful for the possibility to have our clinical trial team enrolled in this story and, most importantly, to help the patients who have exhausted all available therapies.
Congratulations to all involved, especially @GhayasIssa !
FDA Oncology@FDAOncology
FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. fda.gov/drugs/resource… #OCENewsBurst
English
Strong work as usual Dr Issa..more hope for our AML patients
Ghayas Issa@GhayasIssa
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
English
FDA approves #menin inhibitor Revumenib for KMT2Ar #AML. Huge congrats to my mentor @GhayasIssa and everyone involved.
The beginning of a new era in AML treatment
Ghayas Issa@GhayasIssa
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
English
Congratulations on this very important milestone in the treatment of patients with AML! Amazing step forward! #AML #menin @GhayasIssa @MDAndersonNews
Ghayas Issa@GhayasIssa
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
English
The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿@break_cancer
We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration @GhayasIssa @MDAndersonNews
English
@GhayasIssa Great work! Congratulations @GhayasIssa and BTC team!
English